SEC Form 4 · accession 0001477932-18-002905
Nascent Biotech Inc. · NBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lowell Thomas Holden
Officer — CFO · Director
Period of report
Jun 26, 2017
Accepted (ET)
Jun 5, 2018 · 2:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001622057
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 26, 2017 | J | 20,678 | $0.30 | A | 811,382 | D | |
| Common Stock | Sep 27, 2017 | J | 98,354 | $0.25 | A | 909,736 | D | |
| Common Stock | Dec 29, 2017 | J | 7,601 | $0.18 | A | 917,337 | D | |
| Common Stock | Mar 30, 2018 | J | 15,210 | $0.25 | A | 932,547 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were granted as part of the employment contract with the Company.